BMS Demonstrates Commitment to Hematology and Advancing R&D Across Multiple Blood Cancers Through Immuno-Oncology Leadership
Bristol-Myers Squibb Company (BMS) has announced the presentation of clinical research from its hematology portfolio at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria from 11–14 June. BMS will present data for elotuzumab, an investigational immunostimulatory antibody, in relapsed or refractory multiple myeloma; Opdivo (nivolumab), in patients with relapsed or refractory lymphoid malignancies; and Sprycel (dasatinib), in chronic myeloid leukemia.
Data to be presented at EHA exemplify BMS’s commitment to advancing the treatment of blood cancers through its experience in hematology and its transformative science of Immuno-oncology.
Key oral presentations include:
• ELOQUENT-2: A Phase III, open-label study [Abstract #S471] comparing elotuzumab in combination with lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone alone (Ld) in patients with relapsed or refractory multiple myeloma, will be featured in the EHA press briefing on Friday 12 June at 8:30 a.m. CEST and will be presented during the Presidential Symposium, also on 12 June, at 3:45 p.m. CEST. The ELOQUENT-2 study was published in the New England Journal of Medicine on 2 June.
• Study 009: A Phase II, open-label study [Abstract #S103] comparing elotuzumab in combination with bortezomib (a proteasome inhibitor) and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma will be presented in an oral session on 12 June at 12:00 p.m. CEST.
• PREAMBLE: A preliminary analysis of an ongoing, multinational, observational study [Abstract #S148] evaluating the real-world clinical effectiveness of standard treatments, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), in patients with relapsed or refractory multiple myeloma will be presented in an oral session on 12 June at 12:00 p.m. CEST.
• CheckMate -039: Updated data from a Phase 1 study [Abstract #S808] evaluating the safety, tolerability and potential efficacy of Opdivo in several hematologic malignancies, including classical Hodgkin Lymphoma will be presented in an oral session on Sunday, June 14 at 8:45 a.m. CEST.
“BMS is leveraging its broad experience in oncology and leading immuno-oncology science to develop a portfolio of innovative therapies, including a novel modality for multiple myeloma, because we believe patients with blood cancers deserve more,” said Michael Giordano, senior vice president, Head of Development, Oncology, BMS. “These data at EHA illustrate our commitment to transforming survival expectations for more patients with a variety of hematologic malignancies.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance